The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 26, 2013
Filed:
Aug. 16, 2012
Jonathan A. Terrett, Sunnyvale, CA (US);
Sarah L. Pogue, Fremont, CA (US);
Kristopher Toy, San Jose, CA (US);
Lan Yang, Morgan Hill, CA (US);
Chetana Rao-naik, Walnut Creek, CA (US);
Bingliang Chen, Alameda, CA (US);
Jonathan A. Terrett, Sunnyvale, CA (US);
Sarah L. Pogue, Fremont, CA (US);
Kristopher Toy, San Jose, CA (US);
Lan Yang, Morgan Hill, CA (US);
Chetana Rao-Naik, Walnut Creek, CA (US);
Bingliang Chen, Alameda, CA (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.